NASDAQ: VOGXVogenx Inc Stock
$20.06-2.73 (-11.98%)
Updated Oct 1, 2026
VOGX Price
$20.06
Fair Value Price
N/A
Market Cap
$297.99M
52 Week Low
$12.95
52 Week High
$38.41
P/E
N/A
P/B
-167.48x
P/S
N/A
PEG
N/A
Dividend Yield
N/A
Revenue
N/A
Earnings
N/A
Gross Margin
N/A
Operating Margin
N/A
Profit Margin
N/A
Debt to Equity
-1.79
Operating Cash Flow
N/A
Beta
-0.47
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A
VOGX Overview
Vogenx is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapeutics for the treatment of serious diseases associated with dysfunctions in human metabolism, including post-bariatric hypoglycemia (PBH) and gastroparesis. The company's lead product candidate is mizagliflozin, an orally administered, small molecule drug candidate being developed for the treatment of PBH, gastroparesis, and GIP-dependent Cushing's Syndrome.
Zen Rating
Our proven quant model uses 115 proprietary factors, including AI, to determine VOGX's potential to beat the market
CHold
- Stocks with a Zen Rating of Hold (C) had an average return of +5.11% per year. Learn More
Zen Rating Component Grades
C
Zen Rating uses advanced AI algorithms that detect subtle patterns in market data; it anticipates future trends that point to superior stock price results.
Industry: Biotech
Industry Rating
F
VOGX
Ranked#172 of 464
Ranked#172 of 464
Top Ranked Stocks in Industry
| Name / Ticker | Price | Zen Rating |
|---|---|---|
| $9.84 | A | |
| $8.21 | A | |
| $39.57 | A |
Be the first to know about important VOGX news, forecast changes, insider trades & much more!
Overview
Due Diligence Score
–
Industry Average (24)
You've viewed Due Diligence Score for 10/10 free stocks. Upgrade to Premium to see how VOGX scored across 33 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
VOGX's short-term liabilities ($3.19M) exceed its short-term assets ($1.41M)
Short-term Liabilities Financials
VOGX's short-term assets ($1.41M) exceed its long-term liabilities ($0.00)
Long-term Liabilities Financials
VOGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
There are 30 more VOGX due diligence checks available for Premium users.
Valuation
VOGX price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
-167.48x
Industry
5.13x
VOGX's financial health
Profit margin
Revenue
$0.0
Net Income
-$384.4k
Profit Margin
0%
Assets to liabilities
Assets
$1.4M
Liabilities
$3.2M
Debt to equity
-1.79
VOGX's short-term liabilities ($3.19M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
VOGX's short-term assets ($1.41M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
VOGX's debt relative to shareholder... subscribe to Premium to read more.
Shrinking Debt Financials
VOGX's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$27.1k
Investing
$0.0
Financing
$0.0
VOGX vs Biotech Stocks
Vogenx Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.